MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(b) Jeffrey V. Ravetch, M.D., Ph.D. tendered his resignation from the Board of Directors (the “Board”) of MabVax Therapeutics Holdings, Inc. (the “Company”), effective August 3, 2017. Dr. Ravetch expressed his desire to devote more time to his full-time employer, The Rockefeller University. Dr. Ravetch will continue to serve the Company as a scientific consultant and advisor assisting in advancing the promising technology and products that the Company has developed to the terms of his existing two-year consulting agreement with the Company. The existing consulting agreement continues until December 31, 2017, unless further extended by the parties to the agreement. Dr. Ravetch expressed no disagreements between himself and the Company, members of the Board, or members of the Company’s management.
